Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice
about
A method of utrophin up-regulation through RNAi-mediated knockdown of the transcription factor EN1Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout miceAnimal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyAn intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breedTherapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophiesSarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.iNOS ablation does not improve specific force of the extensor digitorum longus muscle in dystrophin-deficient mdx4cv mice.Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null miceDuchenne muscular dystrophy gene therapy: Lost in translation?The FVB Background Does Not Dramatically Alter the Dystrophic Phenotype of Mdx MiceFibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex.AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.Sarcoglycanopathies: molecular pathogenesis and therapeutic prospectsDystrophin-compromised sarcoglycan-δ-knockout diaphragm requires full wild-type embryonic stem cell reconstitution for correction.Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathyProspect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogsThe mouse C2C12 myoblast cell surface N-linked glycoproteome: identification, glycosite occupancy, and membrane orientation.Genomic removal of a therapeutic mini-dystrophin gene from adult mice elicits a Duchenne muscular dystrophy-like phenotypeAAV-directed muscular dystrophy gene therapy.Animal models of human genetic diseases: do they need to be faithful to be useful?The physiological response of protease inhibition in dystrophic muscle.What do mouse models of muscular dystrophy tell us about the DAPC and its components?Myoclonus dystonia and muscular dystrophy: ɛ-sarcoglycan is part of the dystrophin-associated protein complex in brain.Multiple Species Comparison of Cardiac Troponin T and Dystrophin: Unravelling the DNA behind Dilated Cardiomyopathy.Reduced Myocardial Reserve in Young X-Linked Muscular Dystrophy Mice Diagnosed by Two-Dimensional Strain Analysis Combined with Stress Echocardiography.
P2860
Q24306528-1FAD4455-5B80-466C-AEDC-8756ADBC84C0Q27312780-0F335CE5-54C1-4FD4-91C3-5196647A467BQ28084979-7AEA9DA8-A1BF-4C25-9384-117B116D2E64Q30497616-FD445D96-794D-47FC-95A3-BCFC0382D180Q33745227-CFEF32AA-F6F2-4084-8327-D710DDFA4F2FQ33891300-A2AF63B5-5316-4B2E-B163-F6A0EDECA40AQ33955159-4B775D58-2973-4102-9031-8B36FDE53473Q35027817-E5B68B79-EC42-4D8B-8FF0-B10F4B4E2C03Q35052506-6E9D665F-A193-4DDC-9115-EAA139D65FA0Q35117470-2E3B00D8-75B6-4215-A27A-234DB090CDF2Q35145764-76884940-3386-429B-8223-24796846E740Q35169510-3C9B8DF6-72F7-4DDF-AAC7-F1E052FF70FAQ35285784-407CEDA3-BF33-42C7-9D92-048A817EBBEAQ35758335-D5AA5B5C-D9E3-423F-85D1-C9C6D9DB8BD5Q35941963-764CC5CE-8A4C-46F3-A804-7F4F68DDEB58Q36069707-F493CEA7-A383-4156-920D-8BED62BC388EQ36074749-B8325747-B891-49FC-907B-E64AE6FD4ED5Q36506919-3B98220D-92A7-42FB-AE9F-A1817ADD0CFDQ36908212-0B6F5176-C8C4-429F-950F-7120216FB7D9Q37021623-569E78E5-99C4-475A-8AB8-CB8DBCD4B771Q37271889-1F5FD8D4-BE06-4F4A-9E14-BB4CFAE1ABFAQ37412883-02A7BCBF-DF7A-41FD-8232-70BE678D2C31Q37530255-A656C247-9759-4880-A5BB-22655ECCD5A8Q37687423-436A12B9-1297-495B-BF83-9AFF860FB838Q37872654-E831B6FA-C3A2-450A-9BF7-B8197D995780Q38104503-628EDECC-D87B-467A-9B9E-840AE47EA429Q38255744-72961965-2081-448E-92A1-7795EC383090Q41878236-9691935F-FD3D-489D-BC63-545D8E2B6EDBQ48172088-6D972BF0-9862-48FB-A007-C0F687472D13Q48555082-BA0F2E37-5A54-42EB-9008-AC7EF163C7CD
P2860
Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sub-physiological sarcoglycan ...... muscle protection in mdx mice
@en
Sub-physiological sarcoglycan ...... muscle protection in mdx mice.
@nl
type
label
Sub-physiological sarcoglycan ...... muscle protection in mdx mice
@en
Sub-physiological sarcoglycan ...... muscle protection in mdx mice.
@nl
prefLabel
Sub-physiological sarcoglycan ...... muscle protection in mdx mice
@en
Sub-physiological sarcoglycan ...... muscle protection in mdx mice.
@nl
P2093
P2860
P356
P1476
Sub-physiological sarcoglycan ...... muscle protection in mdx mice
@en
P2093
P2860
P304
P356
10.1093/HMG/DDP015
P577
2009-01-08T00:00:00Z